NCT03944304View on ClinicalTrials.gov

Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 27, 2019

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

Paclitaxel

Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).

Trial Locations (1)

05505

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT03944304 - Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | Biotech Hunter | Biotech Hunter